Activity of selpercatinib in RET fusion-positive cancers confirmed
Nature Reviews Clinical Oncology, Published online: 07 October 2022; doi:10.1038/s41571-022-00694-2Activity of selpercatinib in RET fusion-positive cancers confirmed (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - October 7, 2022 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Laparoscopic TME is non-inferior
Nature Reviews Clinical Oncology, Published online: 06 October 2022; doi:10.1038/s41571-022-00695-1Laparoscopic TME is non-inferior (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - October 6, 2022 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Benefit with ESCAT-guided treatment
Nature Reviews Clinical Oncology, Published online: 05 October 2022; doi:10.1038/s41571-022-00693-3Benefit with ESCAT-guided treatment (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - October 5, 2022 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
From ESMO 2022
Nature Reviews Clinical Oncology, Published online: 30 September 2022; doi:10.1038/s41571-022-00691-5From ESMO 2022 (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - September 30, 2022 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Novel combination delivers prolonged OS
Nature Reviews Clinical Oncology, Published online: 30 September 2022; doi:10.1038/s41571-022-00692-4Novel combination delivers prolonged OS (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - September 30, 2022 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
New PEARLS of adjuvant wisdom
Nature Reviews Clinical Oncology, Published online: 29 September 2022; doi:10.1038/s41571-022-00690-6New PEARLS of adjuvant wisdom (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - September 29, 2022 Category: Cancer & Oncology Authors: David Killock Source Type: research
Towards precision oncology with patient-derived xenografts
Nature Reviews Clinical Oncology, Published online: 23 September 2022; doi:10.1038/s41571-022-00682-6Clinical research needs support from preclinical models that consider the biology and genetics of human cancers during treatment, such as patient-derived xenograft (PDX) models. The authors of this Review discuss how PDX models have been used in the past decade for precision oncology and present emerging approaches that could broaden the application of these models. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - September 23, 2022 Category: Cancer & Oncology Authors: Eugenia R. Zanella Elena Grassi Livio Trusolino Source Type: research
Leveraging extrachromosomal DNA to fine-tune trials of targeted therapy for glioblastoma: opportunities and challenges
Nature Reviews Clinical Oncology, Published online: 21 September 2022; doi:10.1038/s41571-022-00679-1Glioblastoma, the most common form of brain cancer in adults, has a dismal prognosis and has proven recalcitrant to novel targeted therapies and immunotherapies. Extrachromosomal DNAs (ecDNAs) harbouring oncogenes are increasingly recognized as important drivers of tumour development, evolution and resistance to treatment, particularly in patients with glioblastoma. In this Perspective, the authors summarize key reasons for the failed clinical translation of new therapies for glioblastoma, highlighting the important contrib...
Source: Nature Reviews Clinical Oncology - September 21, 2022 Category: Cancer & Oncology Authors: Imran Noorani Paul S. Mischel Charles Swanton Source Type: research
Advances in the management of peritoneal malignancies
Nature Reviews Clinical Oncology, Published online: 07 September 2022; doi:10.1038/s41571-022-00675-5Peritoneal surface malignancies (PSMs) typically have a poor prognosis, although considerable advances in the understanding and management of these malignancies have been made over the past decade. This Review comprehensively describes the improvements in knowledge of the biology, assessment and classification, perioperative and surgical management, systemic treatment and pre-emptive management of PSMs. The authors also outline future directions for research in this field. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - September 7, 2022 Category: Cancer & Oncology Authors: Vahan Kepenekian Aditi Bhatt Julien P éron Mohammad Alyami Nazim Benzerdjeb Naoual Bakrin Claire Falandry Guillaume Passot Pascal Rousset Olivier Glehen Source Type: research
Is early-onset cancer an emerging global epidemic? Current evidence and future implications
Nature Reviews Clinical Oncology, Published online: 06 September 2022; doi:10.1038/s41571-022-00672-8The incidence of early-onset forms of many cancers (defined as cancers diagnosed in individuals (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - September 6, 2022 Category: Cancer & Oncology Authors: Tomotaka Ugai Naoko Sasamoto Hwa-Young Lee Mariko Ando Mingyang Song Rulla M. Tamimi Ichiro Kawachi Peter T. Campbell Edward L. Giovannucci Elisabete Weiderpass Timothy R. Rebbeck Shuji Ogino Source Type: research
Synergy of EphB2 and PD-1 blockade
Nature Reviews Clinical Oncology, Published online: 05 September 2022; doi:10.1038/s41571-022-00688-0Synergy of EphB2 and PD-1 blockade (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - September 5, 2022 Category: Cancer & Oncology Authors: David Killock Source Type: research
Senescence and cancer — role and therapeutic opportunities
Nature Reviews Clinical Oncology, Published online: 31 August 2022; doi:10.1038/s41571-022-00668-4The entry of cells into senescence can act as a barrier to tumorigenesis; however, in certain contexts senescent malignant and non-malignant cells can acquire pro-tumorigenic properties. The authors of this Review discuss the cell-intrinsic and cell-extrinsic mechanisms involved in both the antitumorigenic and tumour-promoting roles of senescent cells, and describe the potential of various senolytic and senomorphic therapeutic approaches in oncology. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - August 31, 2022 Category: Cancer & Oncology Authors: Clemens A. Schmitt Boshi Wang Marco Demaria Source Type: research
Are the chronological age cutoffs used in clinical oncology guidelines biologically meaningful?
Nature Reviews Clinical Oncology, Published online: 30 August 2022; doi:10.1038/s41571-022-00684-4Age is one of the strongest risk factors for cancer and also affects tumour biology, treatment recommendations and response to therapy. Although clinical oncology guidelines advocate against classifying patients on the basis of chronological age alone, most studies and published guidelines use discrete age cutoffs, often heterogeneously. Herein, we discuss age cutoffs from a historical and biological perspective, focusing on breast cancer. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - August 30, 2022 Category: Cancer & Oncology Authors: Neil Carleton Priscilla F. McAuliffe Source Type: research
Personalizing the approach to neoadjuvant therapy: a promising path to improving outcomes of resectable melanoma
Nature Reviews Clinical Oncology, Published online: 30 August 2022; doi:10.1038/s41571-022-00677-3Clinical trials of neoadjuvant therapy for melanoma have expanded rapidly over the past several years. Preliminary data demonstrate the prognostic value of pathological response, which might have clinical implications for refining the roles of surgery and adjuvant therapy. These clinical questions are under active investigation across many ongoing clinical trials. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - August 30, 2022 Category: Cancer & Oncology Authors: Giorgos C. Karakousis Tara C. Mitchell Source Type: research
The current state of the art and future trends in RAS-targeted cancer therapies
Nature Reviews Clinical Oncology, Published online: 26 August 2022; doi:10.1038/s41571-022-00671-9The RAS oncogenes are among the most common drivers of tumour development and progression but have historically been considered undruggable. The development of direct KRAS inhibitors has changed this paradigm, although currently clinical use of these novel therapeutics is limited to a select subset of patients, and intrinsic or acquired resistance presents an inevitable challenge to cure. Herein, the authors provide an overview of the RAS pathway in cancer and review the ongoing efforts to develop effective therapeutic strateg...
Source: Nature Reviews Clinical Oncology - August 26, 2022 Category: Cancer & Oncology Authors: Salman R. Punekar Vamsidhar Velcheti Benjamin G. Neel Kwok-Kin Wong Source Type: research
